A Randomized Open-Label Comparison of the Impact of Olanzapine Versus Risperidone on Sexual Functioning

The objective of this study was to compare sexual functioning in patients treated with olanzapine or risperidone. This open-label trial included 46 patients randomized to olanzapine (5-15 mg/d) or risperidone (1-6 mg/d) for 6 weeks. We used sexual dysfunction was assessed by a semistructured intervi...

Full description

Saved in:
Bibliographic Details
Published in:Journal of sex & marital therapy 2006-07, Vol.32 (4), p.315-326
Main Authors: Knegtering, H., Boks, Marco, Blijd, Carl, Castelein, Stynke, van den Bosch, Robert J., Wiersma, Durk
Format: Article
Language:English
Subjects:
Adult
Adult and adolescent clinical studies
Antipsychotic Agents - administration & dosage
Antipsychotic Agents - adverse effects
Benzodiazepines - administration & dosage
Benzodiazepines - adverse effects
Biological and medical sciences
Female
Humans
Male
Medical sciences
Neuropharmacology
Pharmacology. Drug treatments
Prolactin - blood
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychopharmacology
Psychoses
Psychotic Disorders - drug therapy
Risperidone - administration & dosage
Risperidone - adverse effects
Schizophrenia
Schizophrenia - drug therapy
Sexual behavior disorders. Psychogenic sexual dysfunctions
Sexual Dysfunction, Physiological - chemically induced
Sexual Dysfunctions, Psychological - chemically induced
Surveys and Questionnaires
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The objective of this study was to compare sexual functioning in patients treated with olanzapine or risperidone. This open-label trial included 46 patients randomized to olanzapine (5-15 mg/d) or risperidone (1-6 mg/d) for 6 weeks. We used sexual dysfunction was assessed by a semistructured interview based on the items of the UKU side effect rating scale. Three olanzapine-treated patients (12.0%), compared with 11 risperidone-treated patients (52.4%), reported sexual dysfunctions (p = .008) in the semistructured interview. Only 4 patients (8.7%) spontaneously reported sexual dysfunction. The mean dose was 9.4 mg/d for olanzapine and 3.4 mg/d for risperidone. The mean (±SD) prolactin levels (ng/mL) in olanzapine-and risperidone-treated patients were 25.1 (± 23.5) and 43.5 (± 26.1), respectively. Less sexual dysfunction occurred in the group treated with olanzapine compared with the risperidone group. Direct questioning about sexual functioning is necessary to avoid underestimating the frequency of sexual side effects in patients with schizophrenia and related psychotic disorders.
ISSN:0092-623X
1521-0715
DOI:10.1080/00926230600666378